Cargando…
An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
[Image: see text] Severe acute respiratory syndrome (SARS) is caused by a newly emerged coronavirus that infected more than 8000 individuals and resulted in more than 800 (10–15%) fatalities in 2003. The causative agent of SARS has been identified as a novel human coronavirus (SARS-CoV), and its vir...
Autores principales: | Pillaiyar, Thanigaimalai, Manickam, Manoj, Namasivayam, Vigneshwaran, Hayashi, Yoshio, Jung, Sang-Hun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical
Society
2016
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075650/ https://www.ncbi.nlm.nih.gov/pubmed/26878082 http://dx.doi.org/10.1021/acs.jmedchem.5b01461 |
Ejemplares similares
-
Skin whitening agents: medicinal chemistry perspective of tyrosinase inhibitors
por: Pillaiyar, Thanigaimalai, et al.
Publicado: (2017) -
Recent discovery and development of inhibitors targeting coronaviruses
por: Pillaiyar, Thanigaimalai, et al.
Publicado: (2020) -
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective
por: Pillaiyar, Thanigaimalai, et al.
Publicado: (2020) -
Activating endogenous resolution pathways by soluble epoxide hydrolase inhibitors for the management of COVID‐19
por: Manickam, Manoj, et al.
Publicado: (2021) -
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease
por: Kronenberger, Thales, et al.
Publicado: (2023)